AT
Alterity Therapeutics Limited
ATHE · NASDAQ
$3.86 -3.98% (-$0.16)
1M -15.54%
Market Cap $91.6M
P/E Ratio -
Div. Yield -
ROE 62.23%
Bulios Fair Price
$2.67
30.8% downside
Current Price
$3.86
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ATHE is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
84 /100
Cheap P/B 2.14x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 23.27%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
FCF margin N/A
Quality
0 /100
Poor ROIC 56.35%
ROE 62.23%
Asset turnover 0.00x
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 14.52x
Int. coverage N/A
Stability
28 /100
Unstable Beta -0.03x
Rev. volatility 70.61%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ATHE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David A. Stamler
Employees
11
Headquarters
Melbourne
Upcoming events
04 MAR
Earnings
Upcoming earnings report